Why One Drug Is Rarely Enough for Chronic Pain
Pain is not a single signal — it is a complex experience generated through multiple pathways: peripheral nociception, spinal cord processing, central sensitization, emotional and cognitive modulation, and inflammatory amplification. A single drug targeting one pathway leaves the others unaddressed. This is why AAHA/AAFP pain management guidelines (Epstein et al., 2015) explicitly recommend multi-modal analgesia as the standard of care for chronic pain in dogs and cats.
Multi-modal pain management combines interventions with different mechanisms of action to produce additive or synergistic pain relief while potentially reducing the dose (and side effects) of any individual component. For dogs with chronic osteoarthritis, neuropathic pain, cancer-related pain, or post-surgical chronic pain, multi-modal protocols consistently outperform monotherapy in clinical practice.
The Building Blocks
NSAIDs: The Foundation Layer
Non-steroidal anti-inflammatory drugs (carprofen, meloxicam, grapiprant, firocoxib) remain the first-line pharmacologic treatment for inflammatory pain in dogs. They inhibit cyclooxygenase (COX) enzymes, reducing prostaglandin-mediated inflammation and peripheral sensitization.
What NSAIDs do well: Reduce peripheral inflammation, decrease prostaglandin-mediated pain signaling, improve mobility and function in most dogs with OA. What NSAIDs miss: Central sensitization, neuropathic pain, non-inflammatory pain components, and the emotional dimension of chronic pain.
Grapiprant (Galliprant) is a piprant-class NSAID that selectively blocks the EP4 prostaglandin receptor, offering anti-inflammatory effect with a potentially improved GI and renal safety profile compared to traditional COX-inhibiting NSAIDs. It represents a refinement within the NSAID class rather than a fundamentally different approach.
Gabapentin: Addressing Central Sensitization
KuKanich (2013) reviewed the evidence for non-NSAID analgesics in dogs, identifying gabapentin as the most widely used adjunctive analgesic for chronic pain. Gabapentin modulates calcium channels in the spinal cord and brain, reducing central sensitization — the amplification of pain signals by the nervous system that occurs in chronic pain states.
Dosing: Typically 5-10 mg/kg given two to three times daily. Higher doses may be needed for neuropathic pain. The most common side effect is sedation, which usually attenuates within 5-7 days of initiation. Best role: Adjunct to NSAIDs for dogs with inadequate pain control on NSAIDs alone, particularly when pain has a neuropathic component (IVDD, nerve root compression, post-amputation).
Anti-NGF Antibodies: A New Mechanism
Monoclonal antibodies targeting nerve growth factor (anti-NGF therapy) represent the newest pharmacologic class for canine pain management. Bedinvetmab (Librela) and frunevetmab (for cats) block NGF — a key driver of pain sensitization.
Gruen et al. (2021) conducted a placebo-controlled study of frunevetmab in dogs with OA, demonstrating significant improvement in owner-assessed pain and function scores. Anti-NGF antibodies work through a mechanism entirely distinct from NSAIDs and gabapentin, making them genuinely additive in multi-modal protocols.
Dosing: Monthly subcutaneous injection, administered at veterinary clinic. Best role: Dogs with moderate-to-severe OA, particularly those who cannot tolerate NSAIDs or who need additional pain relief beyond NSAID monotherapy.
Tramadol: Diminishing Role
Tramadol was historically widely used as an adjunctive analgesic in dogs, but recent pharmacokinetic and clinical evidence has significantly downgraded its role. Dogs metabolize tramadol differently than humans, producing much less of the active metabolite (O-desmethyltramadol) responsible for opioid-mediated analgesia. Controlled studies have failed to demonstrate efficacy superior to placebo for OA pain in dogs. Its serotonergic effects may provide mild anxiolytic benefit but not meaningful analgesia.
Rehabilitation and Physical Therapies
Therapeutic Laser
Low-level laser therapy (photobiomodulation) applies near-infrared light to tissues, stimulating mitochondrial function, reducing inflammation, and modulating pain signaling. Class IV therapeutic lasers penetrate deep enough to reach joint structures. The evidence supports modest pain reduction as an adjunct, particularly for post-operative pain and chronic joint disease.
Acupuncture
Veterinary acupuncture has moderate evidence for chronic musculoskeletal pain in dogs. Electroacupuncture in particular shows benefit when added to conventional pain management. The mechanism involves endogenous opioid release and dorsal horn pain signal modulation.
Hydrotherapy and Physical Rehabilitation
Aquatic therapy (underwater treadmill, swimming) provides exercise with reduced weight-bearing stress, strengthening periarticular musculature while reducing joint loading. Physical rehabilitation programs combining therapeutic exercise, manual therapy, and modalities (ultrasound, TENS, cryotherapy) improve function through mechanisms independent of pharmacologic analgesia.
Building a Multi-Modal Protocol
Step 1: Single-Agent NSAID Trial
Start with an appropriate NSAID at recommended dose. Assess response objectively using a validated pain scale (CBPI, HCPI, LOAD) at 2-week and 4-week checkpoints.
Step 2: Add Gabapentin if Response Is Insufficient
If NSAID alone provides less than 50% pain reduction, add gabapentin. Start at 5 mg/kg twice daily, titrate to effect (up to 10-20 mg/kg TID for neuropathic pain).
Step 3: Consider Anti-NGF Therapy
If NSAID + gabapentin provides incomplete relief, add monthly bedinvetmab injection. This targets a completely different pain pathway and is genuinely additive.
Step 4: Layer Non-Pharmacologic Therapies
Add rehabilitation exercises, therapeutic laser, or acupuncture based on availability, dog temperament, and response. These provide pain modulation through mechanisms no drug addresses.
Step 5: Monitor and Adjust
Use activity monitoring and serial pain scoring to track response objectively. Adjust components based on response data rather than subjective impression.
When to Involve a Specialist
Referral to a veterinary pain management specialist or rehabilitation specialist is appropriate when:
- Three or more analgesic medications are being used simultaneously
- Pain control remains inadequate despite multi-modal protocol
- The dog has concurrent conditions (kidney disease, liver disease) that limit pharmacologic options
- Post-surgical or cancer-related pain requires complex management
The goal of multi-modal pain management is not to eliminate pain entirely — that is often not achievable in chronic conditions. The goal is to reduce pain to a level that preserves function, activity, and quality of life while minimizing the adverse effect burden of any individual intervention.
Frequently Asked Questions
Why is one pain medication often not enough for chronic pain in dogs?
Chronic pain involves multiple biological pathways — inflammation, nerve sensitization, central processing changes, and muscle spasm. A single drug targets only one pathway, leaving others active. Multi-modal approaches combine drugs and therapies that target different pain mechanisms simultaneously, providing better pain control at lower individual doses with fewer side effects.
What does a typical multi-modal pain plan include for a dog with arthritis?
A comprehensive plan typically combines an NSAID (anti-inflammatory and analgesic), gabapentin (for nerve pain), an omega-3 fatty acid supplement (anti-inflammatory), physical rehabilitation or therapeutic exercise, and environmental modifications (orthopedic bedding, ramps, non-slip surfaces). Acupuncture and laser therapy may be added based on individual response.
Is acupuncture actually effective for pain management in dogs?
Published studies show that veterinary acupuncture produces measurable analgesic effects in dogs with chronic musculoskeletal pain, with improvements in mobility scores and owner-assessed comfort. The evidence is strongest for osteoarthritis pain. Acupuncture is considered a complementary therapy — most effective when combined with pharmaceutical and rehabilitative approaches rather than used alone.
When should a dog be referred to a pain management specialist?
Referral to a veterinary pain management specialist or anesthesiologist is warranted when pain is not adequately controlled with standard NSAID therapy, when the dog cannot tolerate first-line medications, when pain is progressive despite treatment, or when the pain source is complex (neuropathic, cancer-related, or multi-site). Specialists can offer interventional techniques including nerve blocks and epidural therapy.
Bottom Line
Chronic pain in dogs involves multiple pathways — peripheral inflammation, central sensitization, neuropathic signaling, and emotional modulation — and no single drug addresses all of them. Combining NSAIDs with gabapentin, anti-NGF antibodies, and non-pharmacologic therapies like rehabilitation and therapeutic laser produces better pain control with potentially lower doses of each individual component. The stepwise approach — starting with a single NSAID, adding gabapentin if insufficient, then layering additional modalities — provides a structured framework for optimizing pain management while monitoring for side effects.
References
- KuKanich B. Outpatient oral analgesics in dogs and cats beyond nonsteroidal antiinflammatory drugs (Veterinary Clinics of North America Small Animal Practice, 2013).
- Gruen ME et al. A placebo-controlled study of the effects of frunevetmab on chronic pain in dogs with osteoarthritis (Journal of Veterinary Internal Medicine, 2021).
- Lascelles BDX et al. Evaluation of a protocol for developing owner-completed outcome measures for clinical trials in dogs (Veterinary Surgery, 2018).
- Epstein ME et al. AAHA/AAFP pain management guidelines for dogs and cats (Journal of the American Animal Hospital Association, 2015).